A researcher from the University of Missouri School of Medicine has received a $2.8 million grant from the National ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for TransCon ® CNP (navepegritide) for the treatment of children with achondroplasia, a rare ...